Czech Republic Showcases Brilliant Science, Smart Business at BIO 2006

Share Article

CzechInvest, the business and development arm of the Czech Republic, will showcase their country’s emerging biotech capabilities and global business practices at BIO 2006 Chicago International Convention, April 9-12.

CzechInvest, the business and development arm of the Czech Republic, will showcase their country’s emerging biotech capabilities and global business practices at BIO 2006 Chicago International Convention, April 9-12.

Business and biotech experts from the Czech Republic, booth #1730, will highlight their country’s academic, infrastructure and research assets, which are converging with increasing levels of foreign and domestic capital now spurring new research breakthroughs.

“Czech resources and intellectual capital are of growing importance to both the United States and the European Union,” says Radomil Novak, director, U.S. Operations – West and adviser to the CEO, CzechInvest. “We bring to the table the capability of meeting some of the biggest needs of 21st-century biotechnology— solutions that will accelerate development in critical fields.”

The Czech Republic is home to 120 biotech companies. A new biotechnology cluster is under development in Brno – Gregor Mendel’s hometown.

CzechInvest will co-host a seminar about Czech biotechnology, “Biotech Ideas of the Future from the Heart of EU,” from 12:30 p.m. to 1:20 p.m. Sunday, April 9, in Room S405A in the McCormick Place Convention Center.

Speakers include:

  •     Peter Sebo, CSc., head of Laboratory of Molecular Biology of Bacterial Pathogens, Institute of Microbiology, The Academy of Sciences of the Czech Republic, Prague; and member of the Czech Research and Development Council, Prague;
  •     Vladimir Viklicky, CSc., PhD., deputy director of Nuclear Research Institute; director of Radiopharmaceuticals Division of Nuclear Research Institutes; vice chairman of the Czech Republic’s R&D Council; and deputy director of the Institute of Molecular Genetics, The Academy of Sciences of the Czech Republic;
  •     Vaclav Rejholec, CSc., president of the Czech Association of Pharmaceutical Companies and Zentiva’s Prague-based public relations director.

Tana Perglova, head of sector specialists for CzechInvest, says the Czech Republic serves as a “perfect place” for finding biotech partners for both research and development.

“As the Czech Republic becomes an important player in the biotechnology sector, these invited speakers will present and discuss the latest progress and accomplishments of biotech and pharma sectors in our country,” she says.

Czech companies exhibiting at BIO 2006 include:

  •     I.Q.A., the first venture-funded life sciences company in Central and Eastern Europe and a leading independent contract research company in the Czech Republic, develops pharmaceutical products targeted at treating cancer and HIV, and works to improve the performance and effectiveness of established drugs.
  •     Exbio, a 1990 spinoff of The Academy of Sciences of the Czech Republic, manufactures and supplies antibodies for global distribution. Exbio conducts research and development related to hybridoma technology, construction of recombinant proteins and antibodies, and collaborates with leading academic institutions.
  •     Nuclear Research Institute Rez conducts research and development in the field of nuclear technology and radioactive waste management in the power generation industry; designs and provides engineering services in capital construction; produces and distributes radiopharmaceuticals; and operates research reactors.
  •     South Moravian Innovation Centre, founded in 2003, is a coalition of organizations with related biotech interests including Brno University of Technology, Masaryk University, Mendel University of Agriculture and Forestry and the Veterinary and Pharmaceutical University. The center strives to create an environment for innovative biotech companies.
  •     BioTest, a leading contract research laboratory in the Czech Republic, specializes in safety assessment of pharmaceuticals, industrial chemicals, food additives, agrochemicals and other related fields.
  •     BioVendor Laboratory Medicine specializes in the production and distribution of in vitro research products for molecular and cellular laboratory medicine. The company focuses on development of ELISA kits. BioVendor products are distributed worldwide.
  •     Innovation Centre of Biotechnology (BIO) includes a research park, an innovation center and an industrial zone – providing free capacity in the areas of pharmaceutical research and testing.
  •     Silroc CZ produces silicone-nanofiber components for device manufacturers in medical and biotech industries. Special filters are made from nanofiber textiles patented in the Czech Republic. Nanofiber textiles meet the highest filtration requirements – not even micro particles, bacteria or viruses can pass through.
  •     MICEP was established in 2005 by the Czech Republic’s Charles University and its First Faculty of Medicine with the Ministry of Education, Youth and Sports to provide information about Czech research infrastructure and opportunities.
  •     Gryf HB, designing, assembling of industrial technologies for water treatment, measurement and regulation of electrochemical and physical values, controlling of laboratory and industrial fermenters and biotechnologies, equipment for fermentation, bioethanol production and neutralization, visualization and storing of measured values.

About CzechInvest

CzechInvest, the Investment and Business Development Agency, is an agency of the Ministry of Industry & Trade of the Czech Republic whose services and development programs contribute to attracting foreign investment and developing Czech companies. The agency is the sole organization that may submit applications for investment incentives to governing bodies, manage the agenda with related incentives, and manage the development of the entire system of investment support in the Czech Republic. CzechInvest also promotes the country abroad and acts as an intermediary between the European Union and small and medium-sized enterprises in implementing EU structural funds in the Czech Republic.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Melissa Anthony
Visit website